From cardiology's big meeting in Washington, DC
To view this email as a web page, click here

Featured Story

Bristol Myers drug helps patients avoid heart procedure amid FDA countdown

Bristol Myers Squibb is presenting data this weekend that shows its targeted heart drug mavacamten helped reduce the risk of needing septal reduction therapy.

read more

More From ACC 2022

Bayer’s Kerendia cuts cardio and kidney complications in high-risk patients

At the American College of Cardiology conference Monday in Washington, D.C., Bayer presented the latest findings on its diabetic kidney cancer drug Kerendia, discovered by pooling two trials. The company believes the findings will help guide it to more uses for Kerendia.

read more

Massive Chinese smartwatch study screens millions for signs of afib

Using Huawei devices equipped with the same light-based sensors found on Apple Watches, Fitbits and more, researchers found a free app could track a person’s pulse and issue an alert when it falls out of sync.

read more

Medtronic touts 3-year data from its renal denervation system for high blood pressure

Medtronic continues to build up clinical data for its kidney nerve ablation procedure for treating stubborn high blood pressure. A randomized clinical study has shown significant and sustained reductions after three years.

read more

Lexicon hopes sotagliflozin cardio data will set its drug apart from SGLT2 rivals

At the American College of Cardiology in Washington, D.C., Lexicon highlighted results from a trial of sotagliflozin in Type 2 diabetes and kidney disease patients that showed the drug not only reduced heart failure by 26% but also reduced the risk of stroke and heart attack.

read more

Ionis-AstraZeneca antisense drug reduces troublesome cholesterol in phase 2b

Ionis Pharmaceutical, in need of a win after a high profile pipeline flop last week, has found that its AstraZeneca-partnered cholesterol med lowered levels of the troublesome substance in patients during a mid-stage trial. 

read more

iRhythm’s Zio ECG patch catches arrhythmia in older patients, after TAVR implants

More than a decade after first earning the FDA’s sign-off for its Zio ECG patch, iRhythm is still churning out data to prove beyond a shadow of a doubt the heart monitor’s ability to spot atrial fibrillation and other arrhythmias as early as possible.

read more

Philips to bring its 'calming' MRI ambience to the cath lab

Undergoing a medical procedure is always a stressful prospect for a patient—so much so that, at times, their anxieties are simply considered unavoidable. But Philips is looking to make the entire experience just a little less scary.

read more